BPC-157 + TB-500 20mg
High-dose recovery blend combining two of the most researched tissue-support peptides. Full titration schedule and reconstitution math included.
View Full ProtocolEvery protocol built from peer-reviewed research. Dosage math verified. COA authentication guides. Zero conflicts of interest — we sell nothing but knowledge.
Each protocol includes reconstitution math, BAC water volumes, syringe-specific injection volumes, and a full citation chain.
High-dose recovery blend combining two of the most researched tissue-support peptides. Full titration schedule and reconstitution math included.
View Full ProtocolWeekly dose escalation from 0.25mg to 2.4mg. Injection volume by syringe type at each escalation stage. Common errors documented.
View Full ProtocolGHRH + GHRP synergy explained. Reconstitution for 5mg, 10mg, and 20mg blend vials with full dosing schedule and timing guide.
View Full ProtocolNo affiliate links. No sponsored content. No product promotions. Just verified research translated into usable protocols.
From vial to verified injection volume in three clear steps.
All protocols are free to read. Pro unlocks the full PDF library, priority updates, and exclusive community features.
Powered by Stripe · Secure · Cancel anytime
Join thousands of researchers using verified protocols. Free forever, or upgrade to Pro for the full PDF library and monthly digest.
Each protocol includes reconstitution math, BAC water volumes, injection volumes per syringe type, and full citation chain. Comments open under each one.
High-dose recovery blend combining two of the most researched tissue-support peptides. Titration schedule and full reconstitution math included.
View Full ProtocolTriple-agonist GLP-1/GIP/glucagon receptor peptide. Full dosing ramp and weekly dose escalation from Phase 2 trial data.
View Full ProtocolGHRH + GHRP synergy explained. Reconstitution for 5mg, 10mg, and 20mg blend vials with full dosing schedule.
View Full ProtocolWeekly dose escalation from 0.25mg to 2.4mg. Injection volume by syringe type at each escalation stage. Common errors documented.
View Full ProtocolReconstitution for 5mg and 10mg TB-500 vials. Dose range, injection frequency, and storage per clinical literature.
View Full ProtocolIntranasal administration guide. Concentration ratios, drops-per-dose conversion, and storage for combined ACTH/anxiolytic stack.
View Full ProtocolComplete standalone BPC-157 protocol. Subcutaneous and oral administration routes. Reconstitution tables for 5mg and 10mg vials.
View Full ProtocolFirst-generation GHRP comparison guide. Hunger profile, dosing windows, and combination protocol with GHRH analogues.
View Full ProtocolFDA-approved GHRH + GHRP combination. Reconstitution, abdominal fat reduction data from clinical trials, and cycle duration guidance.
View Full ProtocolA Certificate of Analysis is the only third-party evidence of what is actually in a vial. Learn to distinguish legitimate lab reports from fabricated documents in under two minutes.
| Report Number: | RPT-2024-09847-A |
| Date Sample Received: | 2024-08-10 |
| Date of Analysis: | 2024-08-14 |
| Product: | BPC-157 Research Peptide |
| Lot / Batch: | LOT-BPC-240810-04 |
| HPLC Purity: | 98.7% |
| MS Molecular Weight: | 1419.53 Da (Exp: 1419.54 Da) |
| Endotoxin (LAL): | <0.10 EU/mg |
| Analyst: | Dr. M. Patterson (signed) |
| QA Sign-off: | J. Reyes – QA Manager |
| Report Number: | COA-001 |
| Date of Analysis: | January 2024 |
| Product: | BPC-157 5mg |
| Lot / Batch: | BPC157 |
| Purity: | 99.00% |
| Molecular Weight: | Confirmed |
| Endotoxin: | Not tested |
| Analyst: | Not signed |
Pro members get the printable 12-point checklist PDF. Keep it on hand every time a new vial arrives.
Community-built database of researcher experiences. Every submission anonymized before publishing. Share your protocol — positive, negative, or inconclusive.
Running BPC-157 + TB-500 20mg blend at 250mcg/day SubQ for 6 weeks. Reconstituted with 4mL BAC water. Used the calculator — 5 units on U-100.
Week 2: Noticeably reduced acute inflammation. Ultrasound at week 4 showed improved tendon architecture. No injection site reactions beyond mild redness at first injection. Did not use NSAIDs during the protocol.
3-week protocol: Semax 600mcg/day intranasal. Persistent nasal irritation began day 4. Discontinued at day 15.
No subjective cognitive enhancement. Mucosa dryness and mild burning. COA showed 98.3% purity — likely not a quality issue. Would try lower dose (200mcg/day) or subcutaneous route. Reporting as failure so others know.
Documenting a reconstitution error: used 0.5mL BAC water on a 5mg vial (10mg/mL) — dose volume too small to measure on U-100.
Corrected to 2.5mL BAC (2mg/mL). 0.25mg dose = 12.5 units on U-100 — measurable. Appetite suppression noticeable by day 4 after correction. Error was entirely reconstitution math.
100mcg/100mcg pre-sleep SubQ for 12 weeks. Reconstituted 10mg blend with 2mL BAC — 4 units on U-100. IGF-1 bloodwork at weeks 6 and 12.
IGF-1 rose from 182 ng/mL to 234 ng/mL at week 6, stabilized at 228 ng/mL at week 12. Sleep quality markedly improved by week 2. No desensitization on 5-on/2-off schedule.
All submissions reviewed before publishing. Identifiers removed. Your data contributes to the aggregate database.
Enter your vial size and target dose. Get exact injection volumes for U-100, U-50, and U-20 syringes instantly.
// Calculation Results
Always verify independently. For educational reference only.